High Volume Subcutaneous Drug Delivery

  • ID: 3736634
  • Report
  • Region: Global
  • Greystone Associates
1 of 3
The Demographics of Patient Populations and the Current Trend in Therapeutic Drug Development are Converging to Create an Increasingly Steep Demand Curve for Infusion
The trend favoring biological drugs as a percent of all drugs continues to accelerate. Most are injectables and many require volumes that exceed 1 ml per dose, the de facto limit for comfortable and safe patient self-administration. As result, the majority of biologicals are supplied for delivery via infusion.

The demographics of patient populations and the current trend in therapeutic drug development are converging to create an increasingly steep demand curve for infusion. The costs and logistics of this convergence are a major driver of the efforts to develop and commercialize high volume drug delivery products that can be administered subcutaneously. It is expected that the number of therapeutic drugs in this class will grow significantly by the end of the decade, creating significant opportunities for high volume subcutaneous drug delivery products.

What You Will Learn

- Provides detailed analysis of therapeutic injectables with high volume dosing requirements that have been developed for subcutaneous administration over extended time periods.
- Analyzes therapeutic demand drivers and evaluates product activity in eleven product segments
- Profiles devices for delivering high volume drugs subcutaneously and assesses design factors and material selection issues
- Examines high volume subcutaneous drug products in development, and analyzes their potential commercial impact
- Provides market data and forecasts to 2020
- Profiles injectable drug and device participants, their product development activities, business strategies, and corporate alliances and affiliations
- Evaluates the impact of economic, technology, and regulatory factors
Note: Product cover images may vary from those shown
2 of 3
1. Executive Summary

2. The Market Opportunity
- Drug Delivery Market Dynamics
- Shifting Demographics
- The Trend toward Self-Administration
- The Cost and Logistical Burden of Out-patient Infusion
- Innovation in Device Designs
- Therapeutic Demand Drivers
- Competitive Landscape
- Risk Factors

3. High Volume Subcutaneous Market Segments
- High Volume Dosing
- Duration Dependent Dosing

4. Device Design Factors
- Human Engineering/Ergonomics
- Usability
- Safety
- Alerts/User Feedback
- Disposable vs. Reusable
- Electronic vs. Mechanical
- Primary Drug Container
- Lyophilized Drugs/Reconstitution

5. Key Therapeutic Sectors
- Antibiotics
- scPharmaceuticals
- Autoimmune
- AstraZeneca
- Cardiology
- scPharmaceuticals
- Insulet
- Hematology
- Amgen
- UCB
- Immunology
- CSL Behring
- Octapharma
- Grifols
- Bio Products Laboratory
- Metabolic Conditions
- GlaxoSmithKline
- Rhythm Metabolic
- Italfarmaco
- Neurology
- AbbVie
- NeuroDerm
- Britannia
- US Worldmeds
- Oncology
- Janssen
- Roche
- Other Therapeutic Segment
- UCB Pharma
- Takeda

6. Company Profiles
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll